Cover Image
市場調查報告書

抗憂鬱症藥,設備,治療方法的全球市場預測

GLOBAL ANTI-DEPRESSANT DRUGS, DEVICES, AND THERAPIES MARKET FORECAST 2017-2025

出版商 Inkwood Research 商品編碼 535790
出版日期 內容資訊 英文 172 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
抗憂鬱症藥,設備,治療方法的全球市場預測 GLOBAL ANTI-DEPRESSANT DRUGS, DEVICES, AND THERAPIES MARKET FORECAST 2017-2025
出版日期: 2017年08月10日 內容資訊: 英文 172 Pages
簡介

本報告提供抗憂鬱症藥,設備,治療方法的全球市場調查,提供整體市場趨勢,抗憂鬱症藥·心理健康用設備·治療方法·各地區的詳細趨勢,市場規模的變化與預測,成長促進·阻礙因素以及市場機會·課題分析,競爭情形,主要企業簡介等系統性資訊。

第1章 調查範圍

第2章 調查手法

第3章 摘要整理

  • 主旨
  • 主要調查結果

第4章 市場決策要素

  • 推動因素
  • 阻礙因素
  • 機會
  • 課題

第5章 抗憂鬱症藥,設備,治療的全球市場:市場區隔

  • 各零件
    • 抗憂鬱症藥市場
      • 絲氨酸和諾貝環素抑製劑(SNRI)
      • 諾貝寧和多巴胺復甦抑製劑(NDRI)
      • 非定型抗憂鬱症藥
      • 單胺氧化酵素抑制劑
      • 其他
    • 心理健康用設備市場
      • 深層腦部刺激器(DBS)
      • 顱電刺激設備(CES)
      • 經顱磁刺激設備(TMS)
    • 治療方法市場
      • 認知行為治療(CBT)
      • 電力痙攣療法(ECT)
      • 理智感情行動療法(REBT)
      • 其他治療方法

第6章 市場分析

  • 波特的五力分析
  • 預測分析
  • 價值鏈分析
    • 抗憂鬱症藥的價值鏈分析
    • 治療設備的價值鏈
  • 主要的購買標準
  • 市場機會的矩陣
  • 業者情勢

第7章 地區分析

  • 北美
    • 美國
    • 加拿大
  • 歐洲
    • EU的醫療費償付政策·規定
    • 英國
    • 法國
    • 德國
    • 西班牙
    • 其他
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 澳洲
    • 其他
  • 其他地區

第8章 企業簡介

  • 競爭情形
    • 主要策略·分析
    • 市場佔有率分析
    • 主要企業分析
  • ABBOT LABORATORIES
  • ALLERGAN PLC
  • BOEHRINGER INGELHEIM GMBH
  • BRAINSWAY
  • CYBERONICS INC
  • ELI LILLY AND COMPANY
  • F. HOFFMANN-LA ROCHE LTD
  • GLAXOSMITHKLINE
  • H. LUNDBECK AS
  • MAYO CLINIC
  • NEURONETICS
  • PFIZER
  • SANOFI
  • SUN PHARMACEUTICALS
  • TEVA PHARMACEUTICALS INDUSTRIES

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: 6732

KEY FINDINGS

The Global Anti-depressant drugs, devices, and therapies market is anticipated to grow at a CAGR of 2.12% over the forecast period of 2017- and 2025. The revenue generated by the market is expected to increase from $ 16442 million in 2016 and reach $19712 million by 2025. The antidepressant drugs, devices, and therapies market is primarily driven because of factors such as a shift in the market from branded to generic drugs, a growing consciousness of depression as a medical disorder and the surge in sales of antidepressants in the past few years.

MARKET INSIGHTS

The market is segmented into types of antidepressants drugs, types of devices and the types of therapies. The Antidepressants drugs are further segmented into Serotonin and norepinephrine reuptake inhibitors (SNRIs), atypical antidepressants, Norepinephrine and dopamine reuptake inhibitors (NDRIs), Tricyclic antidepressants (TCA), Monoamine oxidase inhibitors (MAOIs) etc. The Devices are further segmented into Fisher Wallace Stimulators, Deep Brain Stimulators, Transcranial Magnetic Stimulator, etc. Also, the Therapies segment is further sub-divided into Electroconvulsive Therapy (ECT), Cognitive Behavior Therapy (CBT), Rational-emotive behavior therapy (REBT), etc.

The high cost of depression therapies coupled with the lack of medical insurance coverage for them is a major factor restraining the market growth. However, with the rising awareness about depression being a medical condition, the market is expected to show a huge promise during the forecasted years.

REGIONAL INSIGHTS

Geographically, the global anti-depressant drugs, devices, and therapies market is segmented into:

North America - U.S. & Canada

Asia-Pacific - China, India, Japan, Australia, Rest of APAC

Europe - UK, France, Germany, Spain, Rest of Europe

Rest of World

The North American market is expected to hold the biggest share by 2025 on account of its developed healthcare system and increased expenditure on mental health treatment. Major players such as Eli Lilly, Forest Laboratories, and Pfizer are based in North America. However, this market is facing a possibility of dilution on account of the patent expiry of most of the prescribed drugs. On the contrary, the Asia-Pacific market is expected to be the fastest-growing region for the anti-depressant drugs, devices, and therapies market. The level of awareness regarding depression is steadily increasing in countries such as India, China, Japan, and Korea, thus making this region a prospective market in the coming years.

COMPETITIVE INSIGHTS

Pfizer Inc. is a research-based, global biopharmaceutical company that deals with vaccines, medicines, and consumer healthcare products. TEVA Pharmaceutical Industries is another prominent generic pharmaceutical company that is engaged in the development, production, and marketing of generic, proprietary branded pharmaceuticals and active pharmaceutical ingredients. Some of the other major players include Sun Pharmaceuticals, Eli Lily, Neuronetics, Allergan Plc, Abbot Laboratories, Brainsway, Cyberonics Inc, etc.

1. RESEARCH SCOPE

  • 1.1. STUDY GOALS
  • 1.2. SCOPE OF THE MARKET STUDY
  • 1.3. WHO WILL FIND THIS REPORT USEFUL?
  • 1.4. STUDY AND FORECASTING YEARS

2. RESEARCH METHODOLOGY

  • 2.1. SOURCES OF DATA
    • 2.1.1. SECONDARY DATA
    • 2.1.2. PRIMARY DATA
  • 2.2. TOP DOWN APPROACH
  • 2.3. BOTTOM-UP APPROACH
  • 2.4. DATA TRIANGULATION
  • 2.5. ESTIMATION METHODOLOGY

3. EXECUTIVE SUMMARY

  • 3.1. MARKET SUMMARY
    • 3.1.1. KEY FINDINGS
      • 3.1.1.1. STIFF COMPETITION BETWEEN GENERIC AND BRANDED DRUGS
      • 3.1.1.2. RISE IN THE NUMBER OF DEPRESSION PATIENTS AND INCREASING AWARENESS LEVEL OF THE ASIAN CONSUMERS
      • 3.1.1.3. A SHIFT IN THE MARKET FROM BRANDED TO GENERIC DRUGS

4. MARKET DYNAMICS

  • 4.1. DRIVERS
    • 4.1.1. BRANDED DRUGS ARE OUTPERFORMING DUE TO HIGH COST COMPARED TO GENERIC DRUGS
    • 4.1.2. SWELLING CONSCIOUSNESS OF DEPRESSION AS A MEDICAL DISORDER
    • 4.1.3. SURGE IN SALES OF ANTIDEPRESSANTS
  • 4.2. RESTRAINTS
    • 4.2.1. HIGH PRICE OF THE DEPRESSION THERAPY
    • 4.2.2. PATENT EXPIRATION FACED BY THE COMPANIES
    • 4.2.3. DELAY IN PRODUCT LAUNCHES
  • 4.3. CHALLENGES
    • 4.3.1. STIFF COMPETITION FROM THE GENERIC DRUG MAKERS
  • 4.4. OPPORTUNITIES
    • 4.4.1. HUGE MARKET POTENTIAL
    • 4.4.2. MORE INTENDED FOR PERSONNEL THERAPY AND DEVICES TREATMENT

5. SEGMENTATION

  • 5.1. MARKET BY COMPONENTS 2017-2025
    • 5.1.1. MARKET BY ANTIDEPRESSANTS 2017-2025
      • 5.1.1.1. SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITORS (SNRIS)
      • 5.1.1.2. NOREPINEPHRINE AND DOPAMINE REUPTAKE INHIBITORS (NDRIS)
      • 5.1.1.3. ATYPICAL ANTIDEPRESSANTS
      • 5.1.1.4. MONOAMINE OXIDASE INHIBITORS (MAOIS)
      • 5.1.1.5. OTHER MEDICATIONS
    • 5.1.2. MARKET BY MENTAL HEALTH DEVICES
      • 5.1.2.1. GLOBAL DEEP BRAIN SIMULATOR MARKET
      • 5.1.2.2. FISHER WALLACE STIMULATOR
      • 5.1.2.3. TRANSCRANIAL MAGNETIC SIMULATOR (TMS)
      • 5.1.2.4. OTHER DEVICES
    • 5.1.3. MARKET BY THERAPIES 2017-2025
      • 5.1.3.1. COGNITIVE BEHAVIOR THERAPY (CBT)
      • 5.1.3.2. ELECTROCONVULSIVE THERAPY (ECT)
      • 5.1.3.3. RATIONAL EMOTIVE BEHAVIOR THERAPY (REBT)
      • 5.1.3.4. OTHER THERAPIES

6. KEY ANALYTICALS

  • 6.1. PORTERS 5 FORCES MODEL
    • 6.1.1. THREAT OF NEW ENTRANTS
    • 6.1.2. THREAT OF SUBSTITUTE PRODUCTS
    • 6.1.3. BARGAINING POWER OF BUYER
    • 6.1.4. BARGAINING POWER OF SUPPLIER
    • 6.1.5. INTENSITY OF COMPETITIVE RIVALRY
  • 6.2. ESTIMATION ANALYSIS
    • 6.2.1. INCREASING PREVALENCE OF MENTAL HEALTH PROBLEMS
    • 6.2.2. RISING HEALTHCARE EXPENDITURE ACROSS THE GLOBE
    • 6.2.3. RISING GERIATRIC POPULATION
  • 6.3. VALUE CHAIN ANALYSIS
    • 6.3.1. FOR DRUGS
      • 6.3.1.1. MANUFACTURERS
      • 6.3.1.2. DISTRIBUTORS
      • 6.3.1.3. RETAILERS
      • 6.3.1.4. END-USERS
    • 6.3.2. FOR DEVICES
      • 6.3.2.1. MANUFACTURERS
      • 6.3.2.2. DISTRIBUTORS
      • 6.3.2.3. END-USERS
  • 6.4. KEY BUYING CRITERIA
  • 6.5. OPPORTUNITY MATRIX
  • 6.6. VENDOR LANDSCAPE

7. GEOGRAPHY

  • 7.1. NORTH AMERICA
    • 7.1.1. UNITED STATES
    • 7.1.2. CANADA
  • 7.2. EUROPE
    • 7.2.1. REGULATIONS AND REIMBURSEMENT POLICIES IN THE EUROPEAN UNION
    • 7.2.2. UNITED KINGDOM
    • 7.2.3. FRANCE
    • 7.2.4. GERMANY
    • 7.2.5. SPAIN
    • 7.2.6. REST OF THE EUROPE
  • 7.3. ASIA PACIFIC
    • 7.3.1. CHINA
    • 7.3.2. INDIA
    • 7.3.3. JAPAN
    • 7.3.4. AUSTRALIA
    • 7.3.5. REST OF ASIA PACIFIC
  • 7.4. REST OF WORLD

8. COMPANY PROFILE

  • 8.1. COMPETITIVE ANALYSIS
    • 8.1.1. KEY STRATEGIES AND ANALYSIS
    • 8.1.2. MARKET SHARE ANALYSIS
    • 8.1.3. TOP COMPANY ANALYSIS
  • 8.2. ABBOT LABORATORIES
  • 8.3. ALLERGAN PLC
  • 8.4. BOEHRINGER INGELHEIM GMBH
  • 8.5. BRAINSWAY
  • 8.6. CYBERONICS INC
  • 8.7. ELI LILLY AND COMPANY
  • 8.8. F. HOFFMANN-LA ROCHE LTD
  • 8.9. GLAXOSMITHKLINE
  • 8.10. H. LUNDBECK AS
  • 8.11. MAYO CLINIC
  • 8.12. NEURONETICS
  • 8.13. PFIZER
  • 8.14. SANOFI
  • 8.15. SUN PHARMACEUTICALS
  • 8.16. TEVA PHARMACEUTICALS INDUSTRIES

TABLE LIST

  • TABLE # 1 GLOBAL ANTIDEPRESSANTS DRUGS, DEVICES AND THERAPIES MARKET BY REGION 2017- 2025 ($ MILLION)
  • TABLE # 2 PREVALENCE OF DEPRESSION IN WESTERN EUROPE IN 2016
  • TABLE # 3 REGULATIONS AFFECTING DEPRESSION DRUGS AND THERAPY
  • TABLE # 4 LANDSCAPE OF DRUG EXPIRY AND LAUNCHES IN THE UNITED STATES
  • TABLE # 5 GLOBAL ANTIDEPRESSANTS DRUGS, DEVICES AND THERAPIES MARKET, BY COMPONENTS 2017-2025($ MILLION)
  • TABLE # 6 GLOBAL ANTIDEPRESSANTS DRUGS, DEVICES AND THERAPIES MARKET BY ANTIDEPRESSANTS 2017-2025($ MILLION)
  • TABLE # 7 GLOBAL ANTIDEPRESSANTS MARKET BY GEOGRAPHY 2017-2025($ MILLION)
  • TABLE # 8 MAJOR PLAYERS IN THE SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITORS MARKET
  • TABLE # 9 PRICE OF BUPROPION (WELLBUTRIN)
  • TABLE # 10 MAJOR PLAYERS OF THE NOREPINEPHRINE AND DOPAMINE REUPTAKE INHIBITORS
  • TABLE # 11 PRICE OF TRAZODONE OF DIFFERENT STRENGTH
  • TABLE # 12 MAJOR PLAYERS OF THE ATYPICAL ANTIDEPRESSANTS MARKET
  • TABLE # 13 PRICE OF TOFRANIL OF DIFFERENT STRENGTH
  • TABLE # 14 MAJOR PLAYERS OF THE TRICYCLIC ANTIDEPRESSANTS MARKET
  • TABLE # 15 PRICE OF TRANYLCYPROMINE (PARNATE)
  • TABLE # 16 MAJOR PLAYERS OF THE MONOAMINE OXIDASE INHIBITORS (MAOIS) MARKET
  • TABLE # 17 MAJOR PLAYERS OF THE OTHER ANTIDEPRESSANTS MARKET
  • TABLE # 18 GLOBAL DEPRESSION MARKET BY MENTAL HEALTH DEVICES 2017-2025($ MILLION)
  • TABLE # 19 GLOBAL MENTAL HEALTH DEVICES MARKET BY REGIONS 2017-2025($ MILLION)
  • TABLE # 20 MAJOR PLAYERS OF THE DEEP BRAIN SIMULATION MARKET
  • TABLE # 21 MAJOR PLAYERS IN THE FISHER WALLACE SIMULATOR MARKET
  • TABLE # 22 MAJOR PLAYERS OF THE TRANSCRANIAL MAGNETIC SIMULATOR MARKET
  • TABLE # 23 MAJOR PLAYERS OF THE OTHER DEVICES MARKET
  • TABLE # 24 GLOBAL THERAPIES MARKET 2017-2025($ MILLION)
  • TABLE # 25 GLOBAL THERAPIES MARKET BY REGION WISE 2017-2025($ MILLION)
  • TABLE # 26 GLOBAL ANTIDEPRESSANTS DRUGS, DEVICES AND THERAPIES MARKET BY GEOGRAPHY 2017-2025($ MILLION)
  • TABLE # 27 NORTH AMERICA ANTIDEPRESSANTS DRUGS, DEVICES AND THERAPIES MARKET, 2017-2025 ($ MILLION)
  • TABLE # 28 EUROPE GLOBAL ANTIDEPRESSANTS DRUGS, DEVICES AND THERAPIES MARKET BY COUNTRIES 2017-2025($ MILLION)
  • TABLE # 29 ASIA PACIFIC ANTIDEPRESSANTS DRUGS, DEVICES AND THERAPIES MARKET 2017-2025($ MILLION)
  • TABLE # 30 KEY STRATEGIES FOLLOWED BY COMPANIES WITHIN ANTIDEPRESSANTS DRUGS, DEVICES AND THERAPIES MARKET
  • FIGURE LIST
  • FIGURE # 1 ADULTS AVAILED MENTAL HEALTH TREATMENT IN THE US
  • FIGURE # 2 DYSTHYMIC DISORDER IN THE US
  • FIGURE # 3 GLOBAL ANTIDEPRESSANTS DRUG MARKET IN 2017-2025($ MILLION)
  • FIGURE # 4 ASIA PACIFIC ANTIDEPRESSANTS DRUGS, DEVICES AND THERAPIES MARKET 2017-2025($ MILLION)
  • FIGURE # 5 SAVINGS THROUGH GENERIC DRUG USAGE IN THE UNITED STATES IN 2010-2016 ($ BILLION)
  • FIGURE # 6 GLOBAL ANTIDEPRESSANTS MARKET 2016 & 2025($ MILLION)
  • FIGURE # 7 GLOBAL SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITORS MARKET 2017-2025($ MILLION)
  • FIGURE # 8 GLOBAL NDRIS MARKET 2017-2025($ MILLION)
  • FIGURE # 9 GLOBAL ATYPICAL ANTIDEPRESSANTS MARKET 2017-2025($ MILLION)
  • FIGURE # 10 GLOBAL TRICYCLIC ANTIDEPRESSANTS MARKET 2017-2025 ($ MILLION)
  • FIGURE # 11 GLOBAL MAOIS MARKET 2017-2025 ($ MILLION)
  • FIGURE # 12 GLOBAL OTHER ANTIDEPRESSANTS MARKET 2017-2025($ MILLION)
  • FIGURE # 13 GLOBAL MENTAL HEALTH DEVICES MARKET 2016 & 2025($ MILLION)
  • FIGURE # 14 GLOBAL DEEP BRAIN SIMULATION MARKET 2017-2025($ MILLION)
  • FIGURE # 15 GLOBAL FISHER WALLACE SIMULATOR MARKET 2017-2025($ MILLION)
  • FIGURE # 16 GLOBAL TRANSCRANIAL MAGNETIC SIMULATORMARKET 2017-2025($MILLION)
  • FIGURE # 17 GLOBAL TRANSCRANIAL MAGNETIC SIMULATORMARKET 2017-2025($ MILLION)
  • FIGURE # 18 GLOBAL THERAPIES MARKET 2016 & 2025($ MILLION)
  • FIGURE # 19 GLOBAL COGNITIVE BEHAVIOR MARKET 2017-2025($ MILLION)
  • FIGURE # 20 GLOBAL ELECTROCONVULSIVE THERAPY MARKET 2017-2025($MILLION)
  • FIGURE # 21 GLOBAL RATIONAL EMOTIVE BEHAVIOUR THERAPY MARKET 2017-2025($ MILLION)
  • FIGURE # 22 GLOBAL OTHER THERAPIES MARKET 2017-2025($ MILLION)
  • FIGURE # 23 PREVALENCE OF MENTAL HEALTH DISORDERS ACROSS THE GLOBE BETWEEN PERIOD 2012 AND 2020 (MILLION)
  • FIGURE # 24 RISING GERIATRIC POPULATION ACROSS THE GLOBE FOR PERIOD 2014-2020 (MILLION)
  • FIGURE # 25 VALUE CHAIN OF ANTIDEPRESSANT DRUGS
  • FIGURE # 26 VALUE CHAIN ANALYSIS FOR DEVICE MARKET
  • FIGURE # 27 GLOBAL ANTIDEPRESSANTS DRUGS, DEVICES AND THERAPIES MARKET BY GEOGRAPHY 2016 & 2025($ MILLION)
  • FIGURE # 28 UNITED STATES ANTIDEPRESSANTS DRUGS, DEVICES, AND THERAPIES MARKET 2017-2025($ MILLION)
  • FIGURE # 29 CANADA ANTIDEPRESSANTS DRUGS, DEVICES, AND THERAPIES MARKET 2017-2025($ MILLION)
  • FIGURE # 30 EUROPEAN ANTIDEPRESSANTS DRUGS, DEVICES, AND THERAPIES MARKET 2016 & 2025(%)
  • FIGURE # 31 UNITED KINGDOM ANTIDEPRESSANTS DRUGS, DEVICES, AND THERAPIES MARKET 2017-2025($ MILLION)
  • FIGURE # 32 FRANCE ANTIDEPRESSANTS DRUGS, DEVICES, AND THERAPIES MARKET 2017-2025($ MILLION)
  • FIGURE # 33 GERMANY ANTIDEPRESSANTS DRUGS, DEVICES AND THERAPIES MARKET 2017-2025($ MILLION)
  • FIGURE # 34 SPAIN GLOBAL ANTIDEPRESSANTS DRUGS, DEVICES AND THERAPIES MARKET 2017-2025($ MILLION)
  • FIGURE # 35 CHINA ANTIDEPRESSANTS DRUGS, DEVICES AND THERAPIES MARKET 2017-2025($ MILLION)
  • FIGURE # 36 INDIA ANTIDEPRESSANTS DRUGS, DEVICES AND THERAPIES MARKET 2017-2025($ MILLION)
  • FIGURE # 37 JAPAN ANTIDEPRESSANTS DRUGS, DEVICES AND THERAPIES MARKET 2017-2025($ MILLION)
  • FIGURE # 38 AUSTRALIA ANTIDEPRESSANTS DRUGS, DEVICES, AND THERAPIES MARKET 2017-2025($ MILLION)
  • FIGURE # 39 REST OF ASIA PACIFIC ANTIDEPRESSANTS DRUGS, DEVICES AND THERAPIES MARKET 2017-2025($MILLION)
  • FIGURE # 40 REST OF WORLD ANTIDEPRESSANTS DRUGS, DEVICES AND THERAPIES MARKET 2017-2025($ MILLION)
  • FIGURE # 41 MARKET SHARE OF ANTIDEPRESSANTS DRUG MANUFACTURERS (PERCENTAGE OF SALES), 2016
Back to Top